Neuroendocrine responsivity to clomipramine challenge test in neuroleptic naive psychotic patients before and after treatment with haloperidol

European Psychiatry

Volumn 12, Issue 7, 1997, Pages 362-366

  Angelopoulos, E ^a   Markianos, M ^a   Daskalopoulou, E ^a   Tzemos, J ^a   Stefanis, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Clomipramine test; Cortisol; Drug naive; GH; Haloperidol; Prolactin; Schizophrenia

Indexed keywords

CLOMIPRAMINE; HALOPERIDOL;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION FUNCTION; HUMAN; MALE; NAUSEA; NEUROENDOCRINOLOGY; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SEROTONIN BRAIN LEVEL; VOMITING;

EID: 0030832780     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(97)80006-5     Document Type: Article

References (16)

1. Altar CA, Wasley AM, Neale RF, Stone GA. Typical and atypical antipsychotic occupance of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull. 16:1986;517-525.
2. Anderson IM, Ware CJ, da Rosa-Davis JM, Cowen PJ. Decreased 5-HT-mediated prolactin release in major depression. Br J Psychiatry. 160:1992;372-378.
3. Breir A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res. 14:1995;187-202.
4. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology. 13:1996;177-213.
5. Canton H, Verriele L, Colpaert FC. Binding of typical and atypical antipsychotics to 5-HT1 and 5-HT2 sites: clozapine potently interacts with 5-HT1c sites. Eur J Pharmacol. 191:1990;93-96.
6. Golden RN, Hsiao J, Lane E, Hicks R, Rogers S, Potter WZ. The effects of intravenous clomipramine on neurohormones in normal subjects. J Clin Endocrinol Metab. 68:1989;632-637.
7. Golden RN, Hsiao JK, Lane E, Ekstrom D, Rogers S, Hicks R, et al. Abnormal neuroendocrine responsivity to acute iv clomipramine challenge in depressed patients. Psychiatry Res. 31:1990;39-47.
8. Greenshaw AJ. Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential. Trends Pharm Sci. 14:1993;265-270.
9. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistent schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 45:1988;789-796.
10. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghanian GK, et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients: evidence implicating serotonergic systems in positive symptoms of schizophrenia. Arch Gen Psychiatry. 50:1993;258-263.
11. Laakmann G, Gugath M, Kuss HJ, Zygan K. Comparison of growth hormone and prolactin stimulation induced by clomipramine and desimipramine in man in connection with chlorimipramine metabolism. Psychopharmacology. 82:1984;62-67.
12. Laferrere B, Wurtman RJ. Effects of fenfluramine on serotonin release in brains of anaesthesized rats. Brain Res. 504:1989;258-263.
13. Marshall BD, Glynn SM, Midha KK, Hubbard JW, Bowen LL, Banzett L, et al. Adverse effects of fenfluramine in treatment refractory schizophrenia. J Clin Psychopharmacol. 9:1989;110-115.
14. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 99:1989;S18-S27.
15. Nicholson IR, Chapman JE, Neufeld RWJ. Variability in BPRS definitions of positive and negative symptoms. Schizophr Res. 17:1995;177-185.
16. Peroutka SJ, Snyder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potence. Am J Psychiatry. 137:1980;1518-1522.